Scientific Program
| Friday, November 08
|
||||
| 08:00 | Registrations | |||
| 08.50 | Welcomme message – Constantinos Stefanidis, Adrian Lungu | |||
| 1st session – Introduction to genetics and Immunology
Chairs: Todor Arsov, Zoltan Prohaszka |
||||
| 09:00 | From DNA to Destiny: Transforming Healthcare with Genetics | Todor Arsov | North Macedonia | |
| 09:30 | Immune and Genetic Harmony: The Vital Role of the Complement System | Zoltan Prohaszka | Hungary | |
| 10:00 | Genomic medicine in the courtroom | Todor Arsov | North Macedonia | |
| 2nd session – Primary Hyperoxaluria Session supported by Genesis Pharma Chairs: Constantinos J. Stefanidis, Yaacov FRISHBERG |
||||
| 11:00 | 11:00 Genetics of Nephrocalcinosis and Nephrolithiasis | Gheona ALTARESCU | Israel | |
| 11:30 | Primary Hyperoxalurias- an update | Yaacov FRISHBERG | Israel | |
| 12:00 | Clinical experience in the management of primary hyperoxaluria type 1 | Elena Rusu | Romania | |
| 12:30 | Metabolic Causes for Kidney Stones | Constantinos J. Stefanidis | Greece | |
| 13:00 | Crystal Clear: Decoding Urine Metabolites in Kidney Stones | Dusan Paripovic | Serbia | |
| 13:30 | Q and A – Primary Hyperoxaluaria Roundtable | All Participants | ||
| 3rdsession – Fabry Disease Session supported by Genesis Pharma Chairs: Dimitar Roussinov, Adrian Lungu |
||||
| 15:00 | Challenges in diagnosis and management in Fabry Disease | Gheona ALTARESCU | Romania | |
| 15:30 | Kidney involvement aspects in patients with Fabry Disease – Fundeni Expert Center Experience | Elena Rusu | Romania | |
| 16:00 | Fabry Disease in children – how early can we start treatment | Dimitar Roussinov | Bulgaria | |
| 16:30 | Q and A – Fabry Roundtable | Bogdan Obrisca | Romania | |
| 4th session – Cystinosis, RTA
Chairs: Chairs: Velibor Tasic , Andrei Capitanescu |
||||
| 17:00 | Cystinosis – update on genetics and treatment | Elena Levtchenko – Hoogleraar – on-line | Belgium | |
| 17:30 | Cystinosis – Romanian Experience | Andrei Capitanescu | Romania | |
| 18:00 | From rare to common diseases – the story of SGLT2 Inhibitors | Velibor Tasic | North Macedonia | |
| 18:30 | Renal Tubular acidosis – living physiology | Velibor Tasic | North Macedonia | |
| Saturday, November 09
|
|||
| 5th session – aHUS
Chairs: Nicole van de Kar , Adrian Lungu |
|||
| 09:00 | Optimal treatment duration in complement mediated aHUS | Nicole van de Kar | Holland |
| 09:30 | HLA-DQ heterodimer mismatches in kidney transplant patients | Daniel Turudic, Vaka Sigurjonsdottir, Kim Piburn, Lin Wang, Matthias Niemann, Olafur S. Indridason, Runólfur Pálsson, Paul Grimm, Anat Roitberg-Tambur, Bing Melody Zhang | Croatia |
| 10:00 | The use of C5 inhibitors in kidney transplant for patients with aHUS | Corina Tincu / Bogdan Sorohan | Romania |
| 10:30 | Secondary TMAs – the role of complement blocking therapies | Stefan Lujinski / Bogdan Obrisca | Romania |
| 6th session– aHUS
Chairs: Danko Milosevic, Adrian Lungu |
|||
| 11:15 | 45 minutes aHUS Round Table | All – 5 min each | |
| 12:00 | Meningococcal infection in patients with complement blocking therapies | Aleksandra Vujovic / Tanja Kersnik Levart | Slovenia |
| 12:30 | Homo and heterozygous MCPggaac mutations in the onset of atypical hemolytic uremic syndrome (aHUS) | Danko Milosevic | Croatia |
| 13:00 | Terminal Complemet Inhibition in atypical hemolytic uremic syndrome – a single center experience | Valentin Mocanu / Ismail Gener | Romania |
| 7th session – aHUS and C3GN
Chairs: Dimitar Roussinov, Adrian Lungu |
|||
| 14:30 | Advances in C3 Glomerulopathy: Exploring New Therapies and future directions | Adrian Zugravu | Romania |
| 15:00 | aHUS-clinical challenging case | Nora Abazi Emini | North Macedonia |
| 15:30 | Treatment of factor H antibody aHUS: Plasma exchange and immunosuppression vs Eculizumab | Adrian Lungu | Romania |
| 16:00 | Closing remarks | Constantinos J. Stefanidis / Adrian Lungu | Romania |
| Slovenia | Bulgaria | ||
| Croatia | Romania | ||
| Serbia | Greece | ||
| Bosnia and Herzegovina | Turkey | ||
| Kosovo | |||
| Macedonia | |||
ACCEPTED ABSTRACTS: